Wegener Polyangiitis - Pipeline Review, H1 2016

  • ID: 3775410
  • Drug Pipelines
  • 60 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Bionovis SA
  • ChemoCentryx, Inc.
  • Coherus BioSciences, Inc.
  • Genor BioPharma Co., Ltd.
  • GlaxoSmithKline Plc
  • Panacea Biotec Limited
  • MORE
Wegener Polyangiitis - Pipeline Review, H1 2016

Summary

‘Wegener Polyangiitis - Pipeline Review, H1 2016’, provides an overview of the Wegener Polyangiitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wegener Polyangiitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wegener Polyangiitis and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Wegener Polyangiitis
- The report reviews pipeline therapeutics for Wegener Polyangiitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Wegener Polyangiitis therapeutics and enlists all their major and minor projects
- The report assesses Wegener Polyangiitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Wegener Polyangiitis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Wegener Polyangiitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Wegener Polyangiitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Bionovis SA
  • ChemoCentryx, Inc.
  • Coherus BioSciences, Inc.
  • Genor BioPharma Co., Ltd.
  • GlaxoSmithKline Plc
  • Panacea Biotec Limited
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Wegener Polyangiitis Overview

Therapeutics Development

Pipeline Products for Wegener Polyangiitis - Overview

Wegener Polyangiitis - Therapeutics under Development by Companies

Wegener Polyangiitis - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Wegener Polyangiitis - Products under Development by Companies

Wegener Polyangiitis - Companies Involved in Therapeutics Development

Bionovis SA

Bristol-Myers Squibb Company

ChemoCentryx, Inc.

Coherus BioSciences, Inc.

Genor BioPharma Co., Ltd.

GlaxoSmithKline Plc

Panacea Biotec Limited

Sandoz International GmbH

The International Biotechnology Center (IBC) Generium

Wegener Polyangiitis - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

abatacept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

belimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CCX-168 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Wegener Polyangiitis - Dormant Projects

Wegener Polyangiitis - Discontinued Products

Wegener Polyangiitis - Product Development Milestones

Featured News & Press Releases

Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Wegener Polyangiitis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Wegener Polyangiitis - Pipeline by Bionovis SA, H1 2016

Wegener Polyangiitis - Pipeline by Bristol-Myers Squibb Company, H1 2016

Wegener Polyangiitis - Pipeline by ChemoCentryx, Inc., H1 2016

Wegener Polyangiitis - Pipeline by Coherus BioSciences, Inc., H1 2016

Wegener Polyangiitis - Pipeline by Genor BioPharma Co., Ltd., H1 2016

Wegener Polyangiitis - Pipeline by GlaxoSmithKline Plc, H1 2016

Wegener Polyangiitis - Pipeline by Panacea Biotec Limited, H1 2016

Wegener Polyangiitis - Pipeline by Sandoz International GmbH, H1 2016

Wegener Polyangiitis - Pipeline by The International Biotechnology Center (IBC) Generium, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Wegener Polyangiitis - Dormant Projects, H1 2016

Wegener Polyangiitis - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Wegener Polyangiitis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Bionovis SA
  • ChemoCentryx, Inc.
  • Coherus BioSciences, Inc.
  • Genor BioPharma Co., Ltd.
  • GlaxoSmithKline Plc
  • Panacea Biotec Limited
  • MORE
According to our recently published report 'Wegener Polyangiitis – Pipeline Review, H1 2016'; Wegener Polyangiitis pipeline therapeutics constitutes close to 10 molecules. which approximately 10 molecules are developed by Companies.

Furthermore, the publisher says; Wegener Polyangiitis Wegener Polyangiitis is an uncommon disorder that causes inflammation of blood vessels. This inflammation restricts blood flow to various organs. Signs and symptoms include constantly runny nose, nose bleeds, ear infections, cough, chest pain, skin sores and fever. Predisposing factor includes age. Treatment includes immunosuppressive and corticosteroids.

The report 'Wegener Polyangiitis – Pipeline Review, H1 2016' outlays comprehensive information on the therapeutics under development for Wegener Polyangiitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Wegener Polyangiitis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Pre-Registration, Phase III, Phase II, IND/CTA Filed, Preclinical and Unknown stages are 1, 2, 1, 1, 4 and 1 respectively.
Note: Product cover images may vary from those shown
5 of 6
Bionovis SA
Bristol-Myers Squibb Company
ChemoCentryx, Inc.
Coherus BioSciences, Inc.
Genor BioPharma Co., Ltd.
GlaxoSmithKline Plc
Panacea Biotec Limited
Sandoz International GmbH
The International Biotechnology Center (IBC) Generium
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll